

The role of the community pharmacists in managing patients with diabetes type 2 *EDMOND PISTJA, ALBA THEMELI* MEDICAL HEALTH TRAINING CENTER "SANTA MARIA" LEZHE,ALBANIA



Introduction

Methods

Results

Control of diabetes has become one of the most important components of health care system programs. The management of diabetes is complicated and requires lifelong therapy. Among different strategies for diabetes control, improving medication adherence and patient education plays an important role for optimizing diabetes control.

The study was conducted in a community pharmacy in the city of Lezhe, Albania.

This was a randomized controlled trial, with participants randomly allocated in 2 groups (allocation ratio 1:1). The study showed that the pharmacybased program significantly improved medication adherence and glycaemic control in the IG group. At the beginning of the study patients in both group had minor differences in their demographic characteristics (Table 2) and their HbA1c values and Fasting blood glucose but at the end of the study there was a significant improvement in the IG group.

Community pharmacists are in an ideal position in providing care and education for diabetic patients. Patients education should be focused in improving medication adherence, knowledge of the medications and their side effects and self management of diabetes.

The trusted relationship patient-pharmacist can improve diabetes care and outcome.

Objectives

The objective of this study was to evaluate if a pharmaceutical care program could improve glycaemic control in patients with diabetes type 2. Eligible participants were all adults aged 45 or over with an established diagnose of diabetes, BMI \geq 25 and HbA1c \geq 7.0%

(UKDPS,1998)

The two parallel groups consists of the Control group usual care(CG) where there was no pharmaceutical involvement and the Intervention group (IG) pharmaceutical care, consisting of a regularly follow-up by the pharmacist during a 9 month period.

At each visit the pharmacist had conducted a detailed interview with IG patients, identifying problems leading to poor diabetes control, providing patient education (lifestyle, medication and HbA1c goal to achieve). Also the pharmacist gave to IG patients a pill box and a diary log. To patients of both groups were measured their fasting blood glucose, BMI and HbA1c at the baseline and at the end of the study and also their knowledge of the disease.

(Table 1).

The pharmacists education sessions, use of pill box and follow up appointments proved to be beneficial in improving patients knowledge and also reducing Fasting Blood Glucose and HbA1c in patients in the IG Group. (fig 1)



The aims of the study are :

- To reinforce lifestyle advice given to patients at their annual reviews
- 2. To improve glycaemic control in patients with diabetes and their adherence to medication.
- 3. To encourage participation to support groups.

Table	1
-------	---

	intervention
Control group	aroup

Table 2 Demographic characteristics ofpatients in both groups

		Intervention
	Control group	group
Variable	(n= 60)	(n= 60)
Sex (%)		
Male	41.6 %	41.6 %
Female	58.4 %	58.4 %
Mean age (± SD) (
years)	54.8 ± 5.48	54.65± 4.98
Mean duration of DM		
in years (± SD)	6.4 ± 2.6	6.04± 2.22
Mean Income level		
(%)		
below average	35 %	28.3 %
average	51.7 %	55 %
more than average	13.3 %	16.7 %

fasting plasma glucose	
End knowledge of target waist circumference	
n (%)	Inter Cont
End knowledge of target HB1Ac values	
End low medication adherence n (%)	
End of study	
-	
	0 0.1 0.2 0.3 0.4 0.5 0.6 0.7

Intervention group N= 60
Control group N = 60

Conclusions

- . Pharmacist intervention can significantly improve medication adherence and glycaemic control in patients with diabetes.
- 2. Community pharmacists are valuable members of multi disiplinary healthcare teams in the management of patients

	Control group	group
Variable	(n = 60)	(n= 60)
Mean Hb1Ac (%) (± SD)		
Baseline	7.93 ± 0.58	8.46 ± 0.7
After intervention (9 months)	7.67 ± 0.6	7.14 ± 0.24
Mean fasting blood glucose (mg/dl) (± SD)		
Baseline	221.38 ± 27.96	222.9 ± 26.35
After intervention (9 months)	214.68 ± 28.74	176.11± 9.2
Mean BMI (± SD)		
Baseline	29.2 ± 1.68	29.45 ± 1.44
After intervention (9 months)	28.98 ± 1.45	26.81± 1.38

with diabetes.

References

1. NICE 2008: Clinical guideline 66- type 2 diabetes

2. Wubben DP, Vivian EM, Effects of pharmacist outpatient intervention of patients with diabetes mellitus. Pharmacotherapy 2008:28,(4): 421-436

3. Lean MEJ et al: Obesity, weight loss and prognosis in type 2 diabetes; Diabetic Med (1990):7:228



16th EUROPEAN CONGRESS OF ENDOCRINOLOGY

